Onconetix (ONCO) Company Report

Onconetix, Inc. entered into a Registration Rights Agreement on October 1, 2025, with buyers in connection with a Securities Purchase Agreement.
This agreement grants buyers certain registration rights under the 1933 Act for the resale of Series E Convertible Preferred Stock and Warrants, which are convertible into or exercisable for shares of the Company's common stock.
As of the date of the document, Onconetix, Inc. has 1,550,132 shares of Common Stock issued and outstanding and 16,350 shares of Preferred Stock issued and outstanding (comprising 7 Series C and 16,343 Series D shares).
The agreement outlines "Triggering Events," including the failure to pay indebtedness exceeding $500,000 or if any Preferred Shares remain outstanding on or after April 2, 2027.

Oct 3, 2025, 12:16 PM

Onconetix Announces $12.9 Million Private Placement, Debt Settlement, and Merger Termination

ONCO

Convertible Preferred Issuance

M&A

On September 22, 2025, Onconetix, Inc. completed a private placement financing of approximately $12.9 million through the issuance of Series D Convertible Preferred Stock and Warrants. Approximately $9.3 million of this was paid in cash, with the balance used to offset certain amounts owed to investors.
The company settled an $8.8 million debt to Veru, Inc., by paying $6.3 million in cash from the financing proceeds and converting the remaining $2.5 million of debt into Series D Preferred Stock and warrants.
Onconetix and Ocuvex Therapeutics, Inc. mutually terminated their previously announced definitive merger agreement, which was dated July 16, 2025.
The remaining net cash proceeds from the financing are intended to cover costs associated with the Ocuvex merger termination, and for working capital and general corporate purposes.

Sep 26, 2025, 12:45 PM

Onconetix Subsidiary Proteomedix Licenses Manufacturing IP to Immunovia

ONCO

New Projects/Investments

Revenue Acceleration/Inflection

On September 17, 2025, Onconetix, Inc.'s wholly-owned subsidiary, Proteomedix AG, entered into a licensing agreement with Immunovia AB.
Under the agreement, Proteomedix will provide Immunovia with master cells for antibodies related to three biomarkers for the PancreaSure test and a license for key intellectual property for manufacturing reagents.
Immunovia will make payments totaling $700,000 to Proteomedix in 2025 and 2026, including two $300,000 payments due on September 30, 2025, and March 31, 2026, and a $100,000 payment for materials.
Additionally, Immunovia will pay a 3% royalty on net sales of PancreaSure and other products incorporating the licensed intellectual property from January 1, 2026, through December 31, 2032.

Sep 22, 2025, 12:37 PM

Get instant answers from SEC filings, earnings calls & more